http://www.virginia.edu/uvatoday/newsRelease.php?id=15084
U.Va. Study Questions Health Benefits of Commonly Prescribed Cholesterol-Lowering Medication
"Patients in our study who had ezetimibe added to pre-existing statin therapy experienced on average a 22 percent decrease in their LDL cholesterol levels; however, we found that in these patients, atherosclerosis progressed at a rate of 4 percent per year over the two-year study period," said lead author Dr. Christopher M. Kramer, professor of radiology and medicine in the U.Va. School of Medicine and director of the U.Va. Cardiovascular Imaging Center. "That's a troubling rate of progression that occurred, despite the fall in cholesterol."
U.Va. Study Questions Health Benefits of Commonly Prescribed Cholesterol-Lowering Medication
"Patients in our study who had ezetimibe added to pre-existing statin therapy experienced on average a 22 percent decrease in their LDL cholesterol levels; however, we found that in these patients, atherosclerosis progressed at a rate of 4 percent per year over the two-year study period," said lead author Dr. Christopher M. Kramer, professor of radiology and medicine in the U.Va. School of Medicine and director of the U.Va. Cardiovascular Imaging Center. "That's a troubling rate of progression that occurred, despite the fall in cholesterol."